-=Guardant Health (GH) reported earnings on Tue 12 March 19 (a/h)

REDWOOD CITY, Calif. (AP) _ Guardant Health Inc. (GH) on Tuesday reported a loss of $25.1 million in its fourth quarter.

On a per-share basis, the Redwood City, California-based company said it had a loss of 30 cents.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 36 cents per share.

The provider of oncology testing services posted revenue of $32.9 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $24.6 million.

For the year, the company reported a loss of $85.1 million, or $2.80 per share. Revenue was reported as $90.6 million.

Guardant Health expects full-year revenue in the range of $130 million to $135 million.

Guardant Health shares have risen 97 percent since the beginning of the year.

Earnings this week : March 11 - 15, 2019 (wk 11)

Earnings confirmed for this week

Monday (March 11)

• Morning: None
• Afternoon: ADT COUP KRO OXFD  PETQ SFIX

Tuesday (March 12)

• Morning: DKS IPI KEYW MOMO NOG 
• Afternoon: APEI CLNE COHU EVRI GH QHC NTRA  SENS SNCR SWCH  TEUM ZAGG ZTO  

Wednesday (March 13)

• Morning: DQ EXPR  LXRX  SGRY VRA
• Afternoon: APYX CLDR DOMO FSM GDS KINS MDB NNBR SFS SMTC TLRD

Thursday (March 14)

• Morning: BIOS CNNE DG ERJ GCO HUD INAP LX PPDF RDNT SND TEN UXIN
• Afternoon:  ADBE ASNA AVGO AVID DOCU HEAR HTHT JBL MRAM NDLS ORCL PVTL TERP TLYS TRQ TUSK ULTA VRAY WSC ZUMZ

Friday (March 15)

• Morning: BIOS BKE CTRN DPLO KIRK MDCA

-=Guardant Health (GH) : positive results from a study of its Guardant360 liquid biopsy

Announced positive results from the NILE study, which was a head-to-head comparison of the Guardant360 assay to standard-of-care tissue testing for the identification of guideline-recommended biomarkers in first-line advanced non-small cell lung cancer patients. Per the data, says co, Guardant360 "detected targetable genomic biomarkers at a similar rate to tissue" and thus the data "support the use of blood-based biomarker testing ahead of tissue-based testing for all newly diagnosed advanced NSCLC patients." Shares extend to new all-time highs.